Publications by authors named "B Storti"
Article Synopsis
- A new subset of cerebral amyloid angiopathy (CAA) patients, termed iatrogenic CAA (iCAA), is characterized by early onset and is believed to be caused by medical factors, differing from sporadic CAA (sCAA).
- The study involved analyzing cerebrospinal fluid (CSF) and plasma levels of β-Amyloid and tau proteins in patients diagnosed with either iCAA or sCAA in a clinical setting across two research centers.
- Results indicated that patients with sCAA had more cognitive impairments and cardiovascular risks compared to iCAA patients, but levels of key biomarkers (Aβ40, Aβ42, total tau) in both CSF and plasma were similar between the two groups.
Despite the growing interest in gender medicine, the influence of sex and gender on human diseases, including stroke, continues to be underestimated and understudied. The COVID-19 pandemic has overall impacted not only the occurrence and management of stroke but has also exacerbated sex and gender disparities among both patients and healthcare providers. This paper aims to provide an updated overview on the influence of sex and gender in stroke pathophysiology and care during COVID-19 pandemic, through biological, clinical, psychosocial and research perspectives.
View Article and Find Full Text PDFObjectives: Cerebral amyloid angiopathy (CAA)-related features on neuroimaging often coexist with signs of arteriolosclerosis-small vessel disease on neuroimaging in people with intracranial hemorrhage (ICH). This study aimed at defining the value of amyloid pathology detected by flutemetamol PET in reclassification and stratification of risk of bleeding in people with mixed CAA-arteriolosclerosis features.
Methods: We included consecutive patients admitted to 2 institutions (2018-2023) with spontaneous symptomatic ICH, subarachnoid hemorrhage (SAH), transient focal neurologic episodes (TFNE), or cognitive impairment and MRI showing CAA hallmarks.
Article Synopsis
- Lung cancer, particularly lethal pulmonary adenocarcinomas, often shows mutations in the EGFR gene, making understanding tumor behavior and treatment important.
- Researchers utilized genetically engineered mice to study how tumors evolve and interact with their surrounding environment, identifying specific vulnerable cells and their communication with other cells in the tumor microenvironment.
- The drug Unesbulin, a tubulin binding agent, was found to decrease tumor growth and alter the interactions within the tumor environment, suggesting it could be a promising therapeutic strategy for treating EGFR-mutant lung cancers.